ELI LILLY AND COMPANY (NYSE: LLY)

ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

最近更新时间: 昨天, 7:02PM

1,071.44

14.56 (1.38%)

加入群组

前收盘价格	1,056.88
收盘价格	1,059.01
成交量	5,765,806
平均成交量 (3个月)	3,846,885
市值	960,499,613,696

市盈率 (P/E TTM)	52.62
预期市盈率 (P/E Forward)	33.11
价格/销量 (P/S)	15.98
股市价格/股市净资产 (P/B)	39.66

52周波幅	623.78 (-41%) — 1,111.99 (3%)
利润日期	4 Feb 2026
股息率 (DY TTM)	0.14%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	混合的	看跌
	Drug Manufacturers - General (全球的)	混合的	看跌
股票	Eli Lilly and Company	看涨	看涨

AIStockmoo 评分

0.4

分析师共识	1.5
内部交易活动	1.5
价格波动	-3.0
技术平均移动指标	0.0
技术振荡指标	2.0
平均	0.40

相关股票

股票	市值	DY	P/E（TTM）	P/B
LLY	960 B	0.14%	52.62	39.66
NVS	261 B	3.27%	18.61	5.67
NVO	209 B	2.34%	12.52	7.92
JNJ	497 B	0.60%	19.92	6.33
ABBV	394 B	1.47%	170.09	50.46
MRK	248 B	1.63%	13.12	4.80

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Growth
内部持股比例	0.16%
机构持股比例	83.96%

所有权

姓名	日期	持有股份
Lilly Endowment Inc	30 Sep 2025	95,492,993

52周波幅	623.78 (-41%) — 1,111.99 (3%)
目标价格波幅	948.00 (-11%) — 1,500.00 (-99%)
高	1,500.00 (Citigroup, 40.00%)	购买
中	1,182.00 (10.32%)
低	948.00 (Guggenheim, -11.52%)	购买
平均值	1,165.92 (8.82%)
总计	12 购买, 1 保留
平均价格@调整类型	988.30

公司	日期	目标价格	调整类型	价格@调整类型
B of A Securities	15 Dec 2025	1,268.00 (18.35%)	购买	1,062.19
Wells Fargo	10 Dec 2025	1,200.00 (12.00%)	购买	993.64
BMO Capital	04 Dec 2025	1,200.00 (12.00%)	购买	1,014.49
BMO Capital	06 Nov 2025	1,100.00 (2.67%)	购买	937.44
Bernstein	24 Nov 2025	1,300.00 (21.33%)	购买	1,070.16
Morgan Stanley	24 Nov 2025	1,290.00 (20.40%)	购买	1,070.16
Morgan Stanley	13 Nov 2025	1,171.00 (9.29%)	购买	1,022.87
Truist Securities	19 Nov 2025	1,182.00 (10.32%)	购买	1,049.60
JP Morgan	18 Nov 2025	1,150.00 (7.33%)	购买	1,030.05
Citigroup	12 Nov 2025	1,500.00 (40.00%)	购买	1,017.78
Freedom Capital Markets	10 Nov 2025	950.00 (-11.33%)	保留	966.64
Leerink Partners	10 Nov 2025	1,104.00 (3.04%)	购买	966.64
UBS	07 Nov 2025	1,080.00 (0.80%)	购买	924.37
Cantor Fitzgerald	31 Oct 2025	985.00 (-8.07%)	购买	862.86
Guggenheim	16 Oct 2025	948.00 (-11.52%)	购买	819.38
Guggenheim	08 Oct 2025	948.00 (-11.52%)	购买	845.72
显示更多

名称	平均购买 ($)	平均卖出 ($)	总净额	总净值 ($)
ALVAREZ RALPH	1,062.19	-	11	11,684
FYRWALD J ERIK	1,062.19	-	9	9,560
HEDLEY MARY LYNNE	1,062.19	-	9	9,560
LUCIANO JUAN R	1,062.19	-	14	14,871
SULZBERGER GABRIELLE	1,062.19	-	5	5,311
累积净数量				48
累积净值 ($)				50,985
累积平均购买 ($)				1,062.19
累积平均卖出 ($)				-

名称	持有人	日期	类型	数量	价格	价值 ($)
ALVAREZ RALPH	董事	15 Dec 2025	获得 (+)	11	1,062.19	11,684
FYRWALD J ERIK	董事	15 Dec 2025	获得 (+)	9	1,062.19	9,560
HEDLEY MARY LYNNE	董事	15 Dec 2025	获得 (+)	9	1,062.19	9,560
LUCIANO JUAN R	董事	15 Dec 2025	获得 (+)	14	1,062.19	14,871
SULZBERGER GABRIELLE	董事	15 Dec 2025	获得 (+)	5	1,062.19	5,311

日期	类型	细节
19 Dec 2025	CNBC	Nine of the largest pharma companies ink deals with Trump to lower drug prices
18 Dec 2025	公告	Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
18 Dec 2025	CNBC	Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
16 Dec 2025	公告	Lilly to participate in J.P. Morgan Healthcare Conference
12 Dec 2025	公告	Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
11 Dec 2025	公告	Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
11 Dec 2025	CNBC	Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
09 Dec 2025	公告	Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
09 Dec 2025	公告	Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
09 Dec 2025	公告	Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
09 Dec 2025	CNBC	Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
08 Dec 2025	公告	Lilly declares first-quarter 2026 dividend
08 Dec 2025	公告	Carolyn Bertozzi returns to Lilly board of directors
07 Dec 2025	公告	Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
03 Dec 2025	公告	U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
01 Dec 2025	CNBC	Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
24 Nov 2025	公告	Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
24 Nov 2025	公告	Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
24 Nov 2025	CNBC	Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
19 Nov 2025	公告	Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
18 Nov 2025	公告	Lilly to participate in Citi's 2025 Global Healthcare Conference
17 Nov 2025	CNBC	Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
10 Nov 2025	公告	Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'
07 Nov 2025	CNBC	Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
07 Nov 2025	CNBC	Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
06 Nov 2025	公告	Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
06 Nov 2025	CNBC	Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
06 Nov 2025	公告	Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
06 Nov 2025	CNBC	Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
06 Nov 2025	公告	Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
04 Nov 2025	CNBC	Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
03 Nov 2025	公告	Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
03 Nov 2025	CNBC	Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
02 Nov 2025	CNBC	Where the blockbuster weight loss drug market stands today — and what’s coming next
30 Oct 2025	公告	Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
30 Oct 2025	CNBC	Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
29 Oct 2025	CNBC	Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
29 Oct 2025	公告	LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
29 Oct 2025	公告	Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
28 Oct 2025	CNBC	Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development
28 Oct 2025	公告	Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact
28 Oct 2025	公告	Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
27 Oct 2025	公告	Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
27 Oct 2025	公告	Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
27 Oct 2025	公告	Lilly declares fourth-quarter 2025 dividend
27 Oct 2025	公告	Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
24 Oct 2025	公告	Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
24 Oct 2025	公告	Lilly to Acquire Adverum Biotechnologies
24 Oct 2025	公告	Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
17 Oct 2025	公告	Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
17 Oct 2025	CNBC	Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
16 Oct 2025	公告	Lilly confirms date and conference call for third-quarter 2025 financial results announcement
15 Oct 2025	公告	Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
13 Oct 2025	公告	Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
07 Oct 2025	公告	Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
26 Sep 2025	公告	Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
25 Sep 2025	公告	Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
25 Sep 2025	公告	U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
23 Sep 2025	公告	Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
23 Sep 2025	CNBC	Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
22 Sep 2025	CNBC	Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
显示更多

股息率 (DY TTM)	0.14%
5年平均股息收益率	1.10%
股息支付比率	43.94%

除息日	公告日期	支付日期	详情
14 Feb 2025	09 Dec 2024	10 Mar 2025	1.5 现金
15 Nov 2024	28 Oct 2024	10 Dec 2024	1.3 现金
15 Aug 2024	24 Jun 2024	10 Sep 2024	1.3 现金
15 May 2024	06 May 2024	10 Jun 2024	1.3 现金
14 Feb 2024	08 Dec 2023	08 Mar 2024	1.3 现金
14 Nov 2023	01 Nov 2023	08 Dec 2023	1.13 现金
14 Aug 2023	26 Jun 2023	08 Sep 2023	1.13 现金
12 May 2023	01 May 2023	09 Jun 2023	1.13 现金
14 Feb 2023	12 Dec 2022	10 Mar 2023	1.13 现金
14 Nov 2022	17 Oct 2022	09 Dec 2022	0.98 现金
12 Aug 2022	27 Jun 2022	09 Sep 2022	0.98 现金
13 May 2022	02 May 2022	10 Jun 2022	0.98 现金
14 Feb 2022	13 Dec 2021	10 Mar 2022	0.98 现金
12 Nov 2021	18 Oct 2021	10 Dec 2021	0.85 现金
12 Aug 2021	29 Jun 2021	10 Sep 2021	0.85 现金
13 May 2021	03 May 2021	10 Jun 2021	0.85 现金
11 Feb 2021	14 Dec 2020	10 Mar 2021	0.85 现金
12 Nov 2020	19 Oct 2020	10 Dec 2020	0.74 现金
13 Aug 2020	15 Jul 2020	10 Sep 2020	0.74 现金
14 May 2020	04 May 2020	10 Jun 2020	0.74 现金
13 Feb 2020	16 Dec 2019	10 Mar 2020	0.74 现金
14 Nov 2019	22 Oct 2019	10 Dec 2019	0.645 现金
14 Aug 2019	20 Jun 2019	10 Sep 2019	0.645 现金
16 May 2019	07 May 2019	10 Jun 2019	0.645 现金
14 Feb 2019	19 Dec 2018	08 Mar 2019	0.645 现金
14 Nov 2018	16 Oct 2018	10 Dec 2018	0.5625 现金
14 Aug 2018	19 Jun 2018	10 Sep 2018	0.5625 现金
16 May 2018	07 May 2018	08 Jun 2018	0.5625 现金
14 Feb 2018	11 Dec 2017	09 Mar 2018	0.5625 现金
14 Nov 2017	16 Oct 2017	08 Dec 2017	0.52 现金
11 Aug 2017	19 Jun 2017	08 Sep 2017	0.52 现金
11 May 2017	01 May 2017	09 Jun 2017	0.52 现金
13 Feb 2017	12 Dec 2016	10 Mar 2017	0.52 现金
10 Nov 2016	17 Oct 2016	09 Dec 2016	0.51 现金
11 Aug 2016	20 Jun 2016	09 Sep 2016	0.51 现金
11 May 2016	02 May 2016	10 Jun 2016	0.51 现金
10 Feb 2016	08 Dec 2015	10 Mar 2016	0.51 现金
10 Nov 2015	19 Oct 2015	10 Dec 2015	0.5 现金
12 Aug 2015	15 Jun 2015	10 Sep 2015	0.5 现金
14 May 2015	04 May 2015	10 Jun 2015	0.5 现金
11 Feb 2015	15 Dec 2014	10 Mar 2015	0.5 现金
12 Nov 2014	20 Oct 2014	10 Dec 2014	0.49 现金
13 Aug 2014	16 Jun 2014	10 Sep 2014	0.49 现金
13 May 2014	05 May 2014	10 Jun 2014	0.49 现金
12 Feb 2014	16 Dec 2013	10 Mar 2014	0.49 现金
13 Nov 2013	21 Oct 2013	10 Dec 2013	0.49 现金
13 Aug 2013	18 Jun 2013	10 Sep 2013	0.49 现金
14 May 2013	03 May 2013	10 Jun 2013	0.49 现金
13 Feb 2013	17 Dec 2012	08 Mar 2013	0.49 现金
13 Nov 2012	15 Oct 2012	10 Dec 2012	0.49 现金
13 Aug 2012	19 Jun 2012	10 Sep 2012	0.49 现金
13 Feb 2012	12 Dec 2011	09 Mar 2012	0.49 现金
10 Nov 2011	17 Oct 2011	09 Dec 2011	0.49 现金
11 Aug 2011	20 Jun 2011	09 Sep 2011	0.49 现金
11 May 2011	18 Apr 2011	10 Jun 2011	0.49 现金
11 Feb 2011	13 Dec 2010	10 Mar 2011	0.49 现金
10 Nov 2010	18 Oct 2010	10 Dec 2010	0.49 现金
11 Aug 2010	21 Jun 2010	10 Sep 2010	0.49 现金
12 May 2010	19 Apr 2010	10 Jun 2010	0.49 现金
10 Feb 2010	14 Dec 2009	10 Mar 2010	0.49 现金
10 Nov 2009	19 Oct 2009	10 Dec 2009	0.49 现金
12 Aug 2009	22 Jun 2009	10 Sep 2009	0.49 现金
13 May 2009	20 Apr 2009	10 Jun 2009	0.49 现金
11 Feb 2009	15 Dec 2008	10 Mar 2009	0.49 现金
12 Nov 2008	20 Oct 2008	10 Dec 2008	0.47 现金
13 Aug 2008	20 Jun 2008	10 Sep 2008	0.47 现金
13 Feb 2008	17 Dec 2007	10 Mar 2008	0.47 现金
13 Nov 2007	15 Oct 2007	10 Dec 2007	0.425 现金
13 Aug 2007	21 Jun 2007	10 Sep 2007	0.425 现金
11 May 2007	16 Apr 2007	08 Jun 2007	0.425 现金
13 Feb 2007	18 Dec 2006	09 Mar 2007	0.425 现金
13 Nov 2006	16 Oct 2006	08 Dec 2006	0.4 现金
11 Aug 2006	26 Jun 2006	08 Sep 2006	0.4 现金
11 May 2006	24 Apr 2006	09 Jun 2006	0.4 现金
13 Feb 2006	19 Dec 2005	10 Mar 2006	0.4 现金
10 Nov 2005	17 Oct 2005	09 Dec 2005	0.38 现金
11 Aug 2005	24 Jun 2005	09 Sep 2005	0.38 现金
11 May 2005	18 Apr 2005	10 Jun 2005	0.38 现金
11 Feb 2005	20 Dec 2004	10 Mar 2005	0.38 现金
10 Nov 2004	18 Oct 2004	10 Dec 2004	0.355 现金
11 Aug 2004	28 Jun 2004	10 Sep 2004	0.355 现金
12 May 2004	19 Apr 2004	10 Jun 2004	0.355 现金
11 Feb 2004	15 Dec 2003	10 Mar 2004	0.355 现金
12 Nov 2003	20 Oct 2003	10 Dec 2003	0.335 现金
13 Aug 2003	23 Jun 2003	10 Sep 2003	0.335 现金
13 May 2003	28 Apr 2003	10 Jun 2003	0.335 现金
12 Feb 2003	16 Dec 2002	10 Mar 2003	0.335 现金
13 Nov 2002	21 Oct 2002	10 Dec 2002	0.31 现金
13 Aug 2002	24 Jun 2002	10 Sep 2002	0.31 现金
13 May 2002	15 Apr 2002	10 Jun 2002	0.31 现金
13 Feb 2002	17 Dec 2001	08 Mar 2002	0.31 现金
13 Nov 2001	15 Oct 2001	10 Dec 2001	0.28 现金
13 Aug 2001	25 Jun 2001	10 Sep 2001	0.28 现金
11 May 2001	16 Apr 2001	11 Jun 2001	0.28 现金
13 Feb 2001	18 Dec 2000	09 Mar 2001	0.28 现金
13 Nov 2000	16 Oct 2000	11 Dec 2000	0.26 现金
11 Aug 2000	26 Jun 2000	11 Sep 2000	0.26 现金
11 May 2000	17 Apr 2000	09 Jun 2000	0.26 现金
11 Feb 2000	20 Dec 1999	10 Mar 2000	0.26 现金
10 Nov 1999	18 Oct 1999	10 Dec 1999	0.23 现金
11 Aug 1999	19 Jul 1999	10 Sep 1999	0.23 现金
12 May 1999	19 Apr 1999	10 Jun 1999	0.23 现金
10 Feb 1999	21 Dec 1998	10 Mar 1999	0.23 现金
10 Nov 1998	20 Oct 1998	10 Dec 1998	0.2 现金
12 Aug 1998	20 Jul 1998	10 Sep 1998	0.2 现金
13 May 1998	20 Apr 1998	10 Jun 1998	0.2 现金
11 Feb 1998	15 Dec 1997	10 Mar 1998	0.2 现金
12 Nov 1997	15 Sep 1997	10 Dec 1997	0.2 现金
13 Aug 1997	21 Jul 1997	10 Sep 1997	0.36 现金
13 May 1997	21 Apr 1997	10 Jun 1997	0.36 现金
12 Feb 1997	16 Dec 1996	10 Mar 1997	0.36 现金
13 Nov 1996	21 Oct 1996	10 Dec 1996	0.3425 现金
13 Aug 1996	15 Jul 1996	10 Sep 1996	0.3425 现金
13 May 1996	15 Apr 1996	10 Jun 1996	0.3425 现金
13 Feb 1996	18 Dec 1995	11 Mar 1996	0.3425 现金
13 Nov 1995	17 Oct 1995	11 Dec 1995	0.685 现金
11 Aug 1995	17 Jul 1995	11 Sep 1995	0.645 现金
09 May 1995	17 Apr 1995	12 Jun 1995	0.645 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	1.50	1	0.14
2024	5.20	4	0.67
2023	4.52	4	0.78
2022	3.92	4	1.07
2021	3.40	4	1.23
2020	2.96	4	1.75
2019	2.58	4	1.96
2018	2.25	4	1.94
2017	2.08	4	2.46
2016	2.04	4	2.77
2015	2.00	4	2.37
2014	1.96	4	2.84
2013	1.96	4	3.84
2012	1.47	3	2.98
2011	1.96	4	4.72
2010	1.96	4	5.59
2009	1.96	4	5.49
2008	1.41	3	3.50
2007	1.70	4	3.18
2006	1.60	4	3.07
2005	1.52	4	2.69
2004	1.42	4	2.50
2003	1.34	4	1.91
2002	1.24	4	1.95
2001	1.12	4	1.43
2000	1.04	4	1.12
1999	0.920	4	1.38
1998	0.800	4	0.90
1997	1.28	4	1.84
1996	1.37	4	3.75
1995	1.98	3	7.02
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	22.67%
营业利益率 (TTM)	42.49%
稀释每股收益 (EPS TTM)	12.27
季度收入增长率 (YOY)	45.20%
季度盈利增长率 (YOY)	23.00%

总债务/股东权益 (D/E MRQ)	243.61%
流动比率 (MRQ)	1.37
营业现金流 (OCF TTM)	9.32 B
杠杆自由现金流 (LFCF TTM)	-1.82 B

资产报酬率 (ROA TTM)	16.45%
股东权益报酬率 (ROE TTM)	77.28%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)